CLOV vs CI vs ELV Stock Comparison

Clover Health Investments, Cigna and Elevance Health Prices as of Nov 13, 2026 Peers: Industry group
CI Cigna Group
$296.95 +2.5% 1M +9.6% 1Y
Market cap
$78.25B
P/E
13.0x
Revenue (TTM)
$286.32B
Div. yield
2.08%
Managed Care Healthcare
6 wins
ELV Elevance Health, Inc.
$429.67 +0.4% 1M +30.9% 1Y
Market cap
$92.86B
P/E
18.1x
Revenue (TTM)
$201.83B
Div. yield
1.60%
Managed Care Healthcare
4 wins

Head to Head

12 decided of 12

Cigna leads on 6 of the 12 questions below (Cigna 6, Elevance Health 4, Clover Health Investments 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCLOVCIELVLeader
Larger companyMarket capitalisation $2.65B $78.25B $92.86B ELV
Cheaper on earningsLower P/E, profitable companies only 211.8x 13.0x 18.1x CI
Cheaper on forward earningsLower price / next fiscal year consensus EPS 82.7x 9.1x 14.3x CI
Faster revenue growthRevenue growth, trailing twelve months +54.5% +6.8% +3.6% CLOV
More profitableNet margin, trailing twelve months 0.5% 2.1% 2.5% ELV
Better return on capitalReturn on invested capital — 10.4% 8.3% CI
Less leveragedLower net debt / EBITDA — 1.9x -0.5x ELV
Higher dividend yieldTrailing dividend yield — 2.08% 1.60% CI
Better 1-year returnPrice return, last 12 months +100.8% +9.6% +30.9% CLOV
Better 5-year returnAnnualised price return, 5 years -7.1%/yr +6.4%/yr -0.3%/yr CI
Less volatileAnnualised volatility, 1 year 59.0% 27.0% 35.6% CI
Higher overall scoreMean of the five percentile scores vs peers 57/100 63/100 68/100 ELV

Percentile Scorecard

CLOVCIELV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCLOVCIELV
Valuation 39 #17 of 27 89 #4 of 27 81 #6 of 27
Growth 96 #2 of 26 40 #16 of 26 36 #17 of 26
Profitability 44 #15 of 26 68 #9 of 26 72 #8 of 26
Financial Health 84 #5 of 26 32 #18 of 26 68 #9 of 26
Shareholder Returns 24 #14 of 18 88 #3 of 18 82 #4 of 18
Overall 57 63 68
  • CLOV ranked among 27 companies in Healthcare Payers and Distributors
  • CI ranked among 27 companies in Healthcare Payers and Distributors
  • ELV ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCLOVCIELVSPY
1 month +3.5%+2.5%+0.4% -2.0%
3 months +7.8%+5.1%+7.3% -2.8%
6 months +42.9%+4.1%+9.4% +2.0%
Year to date +111.1%+7.9%+22.6% +10.6%
1 year +100.8%+9.6%+30.9% +12.2%
3 years +391.1%+2.4%-6.9% +68.1%
3 years, per year +70.0%+0.8%-2.4% +18.9%
5 years -30.7%+36.4%-1.7% +61.4%
5 years, per year -7.1%+6.4%-0.3% +10.1%
10 years —+122.2%+221.4% +248.5%
10 years, per year —+8.3%+12.4% +13.3%

Risk

MeasureCLOVCIELVSPY
Volatility, 1Y 59.0%27.0%35.6% 13.6%
Downside volatility, 1Y 48.9%26.7%38.1% 13.9%
Beta vs S&P 500, 1Y 1.110.080.29 1.00
Return / volatility, 1Y 1.710.360.87 0.90
Max drawdown, 5Y -91.8%-33.4%-51.2% -25.4%
From 52-week high -8.3%-6.0%-3.5% -3.2%
52-week high $5.41$315.88$445.45 $779.14
52-week low $1.70$258.08$280.74 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCLOVCIELV
P/E now vs peer median 211.8xmedian 25.2x 13.0xmedian 25.2x 18.1xmedian 25.2x
P/S now vs peer median 1.0xmedian 0.4x 0.3xmedian 0.4x 0.5xmedian 0.4x
EV/EBITDA now vs peer median 170.0xmedian 14.5x 8.1xmedian 14.5x 9.6xmedian 14.5x
P/FCF now vs peer median 20.0xmedian 16.5x 9.5xmedian 16.5x 14.3xmedian 16.5x
P/B now vs peer median 6.8xmedian 2.7x 1.8xmedian 2.7x 2.1xmedian 2.7x
PEG now vs peer median 7.85median 1.72 1.59median 1.72 -7.75median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCLOVCIELV
Revenue $2.74B $286.32B $201.83B
Gross profit $516.60M $59.13B $53.35B
Operating income $12.45M $9.78B $7.70B
Net income $12.45M $6.71B $5.13B
Free cash flow $132.28M $8.27B $6.51B
EPS (diluted) $0.02 $22.71 $23.62
Cash & equivalents $268.07M $6.19B $10.35B
Total debt – $31.14B $30.76B
Shares (diluted) 557.48M 263.79M 217.60M
Enterprise value $1.87B $47.45B -$49.61B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCLOVCIELV
P/E 211.8x 13.0x 18.1x
P/FCF 20.0x 9.5x 14.3x
P/Operating cash flow 19.6x 8.3x 12.2x
P/S 1.0x 0.3x 0.5x
P/B 6.8x 1.8x 2.1x
P/Tangible book 6.8x 4.6x 2.7x
EV/EBITDA 170.0x 8.1x 9.6x
EV/EBIT 186.3x 10.4x 11.4x
EV/Revenue 0.8x 0.4x 0.4x
EV/FCF 17.5x 12.4x 13.5x
EV/Operating cash flow 17.1x 10.8x 11.6x
PEG (3Y EPS CAGR) 7.85 1.59 -7.75

Growth

14 metrics
MetricCLOVCIELV
Revenue growth (1Y) 54.5% 6.8% 3.6%
Revenue CAGR (3Y) 92.5% 14.7% 6.2%
Gross profit growth (1Y) 37.5% -4.4% 4.3%
Gross profit CAGR (3Y) 22.8% -0.1% 5.5%
Operating income growth (1Y) 121.6% 8.3% -9.2%
Operating income CAGR (3Y) 27.6% 5.9% -4.2%
Net income growth (1Y) 121.3% 2.4% -7.4%
Net income CAGR (3Y) 27.1% 6.9% -5.2%
EPS growth (1Y) 119.6% -1.2% -4.5%
EPS CAGR (3Y) 27.0% 8.2% -2.3%
Operating cash flow growth (1Y) 395.0% 8.8% 54.6%
Operating cash flow CAGR (3Y) 39.0% -8.8% -7.2%
Free cash flow growth (1Y) 377.7% 11.1% 72.9%
Free cash flow CAGR (3Y) 38.5% -8.8% -7.6%

Profitability

14 metrics
MetricCLOVCIELV
Gross margin 18.9% 20.7% 26.4%
EBITDA margin 0.5% 4.4% 4.6%
Operating margin 0.5% 3.4% 3.8%
Pretax margin 0.5% 2.9% 3.1%
Net margin 0.5% 2.1% 2.5%
FCF margin 4.8% 2.9% 3.2%
Operating cash flow margin 4.9% 3.3% 3.8%
Return on equity 2.9% 15.5% 11.4%
Return on assets 1.5% 4.3% 4.0%
Return on invested capital – 10.4% 8.3%
Return on capital employed 3.2% 9.6% 9.6%
Asset turnover 3.7x 1.8x 1.6x
Cash conversion (OCF / net income) 10.9x 1.4x 1.5x
Stock comp / revenue 2.0% – 0.1%

Financial Health

11 metrics
MetricCLOVCIELV
Debt / assets – 19.8% 24.1%
Debt / equity – 0.7x 0.7x
Net debt / EBITDA – 1.9x -0.5x
Debt / FCF – 3.8x 4.7x
Liabilities / assets 48.1% 72.3% 65.0%
Equity / assets 51.9% 27.7% 35.0%
Interest coverage – – 5.3x
Current ratio 1.5x 0.8x 1.5x
Quick ratio 0.9x 0.7x 1.2x
Cash ratio 0.9x 0.1x 0.8x
Altman Z-score 4.23 2.82 3.06

Shareholder Returns

7 metrics
MetricCLOVCIELV
Dividend yield – 2.1% 1.6%
Net buyback yield 0.0% 1.7% 2.2%
Shareholder yield 0.0% 3.8% 3.8%
Payout ratio (earnings) – 24.3% –
Payout ratio (FCF) – 19.7% –
Dividend growth (1Y) – 2.1% –
Dividend CAGR (3Y) – 4.6% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCLOVCIELV
Forward P/E 82.7xFY2026 9.1xFY2026 14.3xFY2026
EPS, next fiscal year $0.06FY2026 $32.48FY2026 $30.12FY2026
EPS growth, next FY +50.0%FY2026 +8.8%FY2026 -0.6%FY2026
EPS growth, the year after +83.3% +8.7% +4.2%
Revenue, next fiscal year $2.83BFY2026 $304.63BFY2026 $211.92BFY2026
Revenue growth, next FY +47.2%FY2026 +10.8%FY2026 +7.3%FY2026
Revenue growth, the year after +34.4% -6.8% +0.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCLOVCIELV
Held by institutions 27.6% 89.7% 91.8%
Institutions holding 227 1,704 1,615
Change in shares held, QoQ +14.4% +0.9% +1.7%
Institutions buying 124 838 862
Institutions selling 55 576 542
Buyers to sellers 2.25 1.45 1.59

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CLOVCIELV
CLOV 1.00 0.28 0.31
CI 0.28 1.00 0.50
ELV 0.31 0.50 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CLOV, CI and ELV?

Elevance Health (ELV) is the largest by market capitalisation: Clover Health Investments (CLOV) $2.65B, Cigna (CI) $78.25B, Elevance Health (ELV) $92.86B.

Which stock is cheaper, CLOV, CI and ELV?

Cigna (CI) trades on the lowest price-to-earnings ratio (Clover Health Investments (CLOV) 211.8x, Cigna (CI) 13.0x, Elevance Health (ELV) 18.1x). On next year's consensus earnings, Cigna (CI) is cheapest (Clover Health Investments (CLOV) 82.7x, Cigna (CI) 9.1x, Elevance Health (ELV) 14.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Clover Health Investments (CLOV) grew revenue fastest over the trailing twelve months: Clover Health Investments (CLOV) +54.5%, Cigna (CI) +6.8%, Elevance Health (ELV) +3.6%.

Which company is more profitable?

Elevance Health (ELV) has the highest net margin (Clover Health Investments (CLOV) 0.5%, Cigna (CI) 2.1%, Elevance Health (ELV) 2.5%). On return on invested capital, Cigna (CI) leads (Cigna (CI) 10.4%, Elevance Health (ELV) 8.3%).

Which stock has performed better?

Over the past year Clover Health Investments (CLOV) returned the most: Clover Health Investments (CLOV) +100.8%, Cigna (CI) +9.6%, Elevance Health (ELV) +30.9%. Over five years, Cigna (CI) compounded fastest (Clover Health Investments (CLOV) -7.1%/yr, Cigna (CI) +6.4%/yr, Elevance Health (ELV) -0.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Cigna (CI) has the highest dividend yield: Cigna (CI) 2.08%, Elevance Health (ELV) 1.60%. Clover Health Investments (CLOV) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Cigna (CI) has been the steadiest (Clover Health Investments (CLOV) 59.0%, Cigna (CI) 27.0%, Elevance Health (ELV) 35.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CLOV, CI and ELV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cigna (CI) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.